PMID- 31533940
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20210514
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 28
IP  - 12
DP  - 2019 Dec
TI  - Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with 
      Shorter Survival of Patients with Advanced Pancreatic Cancer.
PG  - 2062-2069
LID - 10.1158/1055-9965.EPI-19-0370 [doi]
AB  - BACKGROUND: Pancreatic cancer is associated with development of cachexia, a 
      wasting syndrome thought to limit survival. Few studies have longitudinally 
      quantified peripheral tissues or identified biomarkers predictive of future 
      tissue wasting. METHODS: Adipose and muscle tissue were measured by computed 
      tomography (CT) at diagnosis and 50 to 120 days later in 164 patients with 
      advanced pancreatic cancer. Tissue changes and survival were evaluated by Cox 
      proportional hazards regression. Baseline levels of circulating markers were 
      examined in relation to future tissue wasting. RESULTS: Compared with patients in 
      the bottom quartile of muscle change per 30 days (average gain of 0.8 +/- 2.0 
      cm(2)), those in the top quartile (average loss of 12.9 +/- 4.9 cm(2)) had a hazard 
      ratio (HR) for death of 2.01 [95% confidence interval (CI), 1.12-3.62]. Patients 
      in the top quartile of muscle attenuation change (average decrease of 4.9 +/- 2.4 
      Hounsfield units) had an HR of 2.19 (95% CI, 1.18-4.04) compared with those in 
      the bottom quartile (average increase of 2.4 +/- 1.6 Hounsfield units). Changes in 
      adipose tissue were not associated with survival. Higher plasma branched chain 
      amino acids (BCAA; P = 0.004) and lower monocyte chemoattractant protein-1 
      (MCP-1; P = 0.005) at diagnosis were associated with greater future muscle loss. 
      CONCLUSIONS: In patients with advanced pancreatic cancer, muscle loss and 
      decrease in muscle density in 2 to 4 months after diagnosis were associated with 
      reduced survival. BCAAs and MCP-1 levels at diagnosis were associated with 
      subsequent muscle loss. IMPACT: BCAAs and MCP-1 levels at diagnosis could 
      identify a high-risk group for future tissue wasting.
CI  - (c)2019 American Association for Cancer Research.
FAU - Babic, Ana
AU  - Babic A
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts. ababic1@partners.org.
FAU - Rosenthal, Michael H
AU  - Rosenthal MH
AUID- ORCID: 0000-0002-5085-3904
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
AD  - Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
FAU - Bamlet, William R
AU  - Bamlet WR
AUID- ORCID: 0000-0003-2903-1284
AD  - Mayo Clinic Cancer Center, Rochester, Minnesota.
FAU - Takahashi, Naoki
AU  - Takahashi N
AD  - Mayo Clinic Cancer Center, Rochester, Minnesota.
FAU - Sugimoto, Motokazu
AU  - Sugimoto M
AUID- ORCID: 0000-0002-1654-0613
AD  - Mayo Clinic Cancer Center, Rochester, Minnesota.
FAU - Danai, Laura V
AU  - Danai LV
AD  - Department of Biochemistry and Molecular Biology, University of Massachusetts 
      Amherst, Amherst, Massachusetts.
FAU - Morales-Oyarvide, Vicente
AU  - Morales-Oyarvide V
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Khalaf, Natalia
AU  - Khalaf N
AUID- ORCID: 0000-0002-7585-6183
AD  - Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's 
      Hospital, Boston, Massachusetts.
FAU - Dunne, Richard F
AU  - Dunne RF
AD  - Division of Hematology/Oncology, University of Rochester Medical Center, 
      Rochester, New York.
FAU - Brais, Lauren K
AU  - Brais LK
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Welch, Marisa W
AU  - Welch MW
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Zellers, Caitlin L
AU  - Zellers CL
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Dennis, Courtney
AU  - Dennis C
AD  - Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
FAU - Rifai, Nader
AU  - Rifai N
AD  - Department of Pathology, Boston Children's Hospital, Boston, Massachusetts.
FAU - Prado, Carla M
AU  - Prado CM
AD  - Department of Agricultural, Food and Nutritional Science, University of Alberta, 
      Edmonton, Canada.
FAU - Caan, Bette
AU  - Caan B
AD  - Kaiser Permanente Division of Research, Oakland, California.
FAU - Sundaresan, Tilak K
AU  - Sundaresan TK
AD  - Kaiser Permanente San Francisco, San Francisco, California.
FAU - Meyerhardt, Jeffrey A
AU  - Meyerhardt JA
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Kulke, Matthew H
AU  - Kulke MH
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
AD  - Boston University and Boston Medical Center, Section of Hematology/Oncology, 
      Boston, Massachusetts.
FAU - Clish, Clary B
AU  - Clish CB
AD  - Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
FAU - Ng, Kimmie
AU  - Ng K
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Vander Heiden, Matthew G
AU  - Vander Heiden MG
AUID- ORCID: 0000-0002-6702-4192
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
AD  - Koch Institute for Integrative Cancer Research and Department of Biology, 
      Massachusetts Institute of Technology, Cambridge, Massachusetts.
FAU - Petersen, Gloria M
AU  - Petersen GM
AD  - Mayo Clinic Cancer Center, Rochester, Minnesota.
FAU - Wolpin, Brian M
AU  - Wolpin BM
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts.
LA  - eng
GR  - P30 DK040561/DK/NIDDK NIH HHS/United States
GR  - U01 CA215798/CA/NCI NIH HHS/United States
GR  - U01 CA210171/CA/NCI NIH HHS/United States
GR  - K07 CA222159/CA/NCI NIH HHS/United States
GR  - R01 CA205406/CA/NCI NIH HHS/United States
GR  - KL2 TR001999/TR/NCATS NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190918
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
SB  - IM
MH  - Adipose Tissue/diagnostic imaging/*physiopathology
MH  - *Body Composition
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/diagnostic imaging/*physiopathology
MH  - Pancreatic Neoplasms/diagnostic imaging/*mortality/pathology
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tomography, X-Ray Computed/*methods
PMC - PMC6891169
MID - NIHMS1539040
EDAT- 2019/09/20 06:00
MHDA- 2020/09/12 06:00
PMCR- 2020/06/01
CRDT- 2019/09/20 06:00
PHST- 2019/04/03 00:00 [received]
PHST- 2019/05/29 00:00 [revised]
PHST- 2019/08/27 00:00 [accepted]
PHST- 2019/09/20 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2019/09/20 06:00 [entrez]
PHST- 2020/06/01 00:00 [pmc-release]
AID - 1055-9965.EPI-19-0370 [pii]
AID - 10.1158/1055-9965.EPI-19-0370 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2062-2069. doi: 
      10.1158/1055-9965.EPI-19-0370. Epub 2019 Sep 18.